64320-89-4

Basic information

• Product Name: 4-(hydroxymethyl)pyrrolidin-2-one
• Synonyms: 4-(hydroxymethyl)pyrrolidin-2-one;2-pyrrolidinone, 4-(hydroxymethyl)-;4-(HydroxyMethyl)-2-pyrrolidin-2-one;3-(Hydroxymethyl)pyrrolidin-5-one, 4-(Hydroxymethyl)-2-oxopyrrolidine;4-methylol-2-pyrrolidone
• CAS NO: 64320-89-4
• Molecular Formula: C₅H₉NO₂
• Molecular Weight: 115.13046
• Product Categories: Amines;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 64320-89-4.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 345.953 °C at 760 mmHg
• Flash Point: 163.027 °C
• Appearance: /
• Density: 1.153 g/cm³
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 14.56±0.10(Predicted)
• CAS DataBase Reference: 4-(hydroxymethyl)pyrrolidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(hydroxymethyl)pyrrolidin-2-one(64320-89-4)
• EPA Substance Registry System: 4-(hydroxymethyl)pyrrolidin-2-one(64320-89-4)

Safety Data

• Hazard Codes: Xi,N
• Statements: 36-51/53
• Safety Statements: 26-61
• RIDADR: UN3077
• HazardClass: IRRITANT
• Hazardous Substances Data: 64320-89-4(Hazardous Substances Data)

Usage

Description

4-(hydroxymethyl)pyrrolidin-2-one is an organic compound that serves as a key intermediate in the synthesis of various pharmaceutical compounds. It is characterized by its unique structure, which includes a pyrrolidin-2-one ring with a hydroxymethyl group attached to the 4-position. This structural feature allows it to be a versatile building block in the development of new drugs and therapeutic agents.

Uses

Used in Pharmaceutical Industry:
4-(hydroxymethyl)pyrrolidin-2-one is used as an intermediate in the preparation of aminopiperidines and related compounds. These compounds act as MCH (melanin-concentrating hormone) receptor modulators, which have potential therapeutic applications in the treatment of various disorders in humans. Specifically, they can be used to address metabolic, feeding, and sexual disorders by modulating the activity of the MCH receptor, thereby influencing the physiological processes associated with these conditions.

Upstream product

• 35309-35-4 5-oxopyrrolidine-3-carboxylic acid methyl ester 
• 181941-94-6 diethyl 2-[1-(diphenylmethyl)azetidin-3-yl]propane-1,3-dioate 
• 183062-93-3 1-Benzhydryl-4-hydroxymethyl-2-oxo-pyrrolidine-3-carboxylic acid 
• 183062-94-4 1-Benzhydryl-4-hydroxymethyl-pyrrolidin-2-one 

Downstream Products

• 64318-92-9 4-(2-tetrahydropyranyl-oxymethyl)-pyrrolidone 
• 945671-51-2 4-(bromomethyl)pyrrolidin-2-one 
• 133749-56-1 1-(4-bromophenyl)-4-(hydroxymethyl)pyrrolidin-2-one 
• 1207840-66-1 5-((pyrrolidin-2-on-4-yl)methylhydroxy)-7-(4-(dimethylamino)-3-methylphenyl)-[1,6]naphthyridine 
• 1207540-19-9 4-[7-(4-morpholin-4-yl-phenyl)-[1,6]naphthyridin-5-yloxymethyl]-pyrrolidin-2-one 

Relevant articles and documents

Oxazolidinone compounds and its use in medicine (by machine translation)

The invention relates to a benzoxazole compound alkane ketones, and its in the preparation of the prevention and treatment of thromboembolic disease in the application. In particular, the invention relates to the general formula (I)) the compound, among them or their stereoisomers, geometric isomers, tautomers, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug, the variables are defined in the specification. The invention also relates to the general formula (I) compound of formula its stereoisomers, geometric isomers, tautomers, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or salt of a prodrug use as pharmaceuticals, in particular as used for the prevention and treatment of thromboembolic disease of use. (by machine translation)

Discovery of orally available integrin α5β1 antagonists

Previous research within our laboratories identified the 3-hydroxypyrrolidine scaffold 1 as a new and selective integrin α5β1 inhibitor class which was designed for local administration. Herein the discovery of new orally available integrin α5β1 inhibitor scaffolds for potential systemic treatment is described.